AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	11.09	10.13	6.1	4.51
Research & Development	45.74	39.31	26.31	19.42
Other Operating Expenses	-2.27	-1.42	-1.22	-1.3
Operating Expenses	54.56	48.02	31.19	22.63
Operating Income	-54.56	-48.02	-31.19	-22.63
Interest Expense	-0.04	-0.07	-0.03	-0.05
Interest & Investment Income	1.5	1.22	0.25	0.07
Currency Exchange Gain (Loss)	-0.23	-0.23	0.01	-0.09
Other Non Operating Income (Expenses)	-3.54	0.84	18.96	11.89
Pretax Income	-56.87	-46.26	-12.01	-10.81
Income Tax Expense	0	0	-0.62	-2.66
Net Income	-56.88	-46.27	-11.39	-8.14
Preferred Dividends & Other Adjustments	15.39	11.58	7.89	5.42
Net Income to Common	-72.27	-57.85	-19.28	-13.56
Shares Outstanding (Basic)	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0
EPS (Basic)	-2890.60	-2314.04	-771.28	-542.56
EPS (Diluted)	-2890.60	-2314.04	-771.28	-542.56
Free Cash Flow	-51.37	-47.5	-24.59	-18.97
Free Cash Flow Per Share	-2054.80	-1900.12	-983.68	-758.68
EBITDA	-54.43	-47.97	-31.09	-22.61
D&A For EBITDA	0.13	0.06	0.1	0.02
EBIT	-54.56	-48.02	-31.19	-22.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q